Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RPL34P6 (ribosomal protein L34 pseudogene 6) is a processed pseudogene in the human genome, officially approved by HGNC as HGNC:35810. Pseudogenes are DNA segments that resemble functional genes but are generally nonfunctional due to mutations or absence of regulatory elements. RPL34P6 is related to the ribosomal protein L34 (which is a protein-coding gene and a component of the large ribosomal 60S subunit), but RPL34P6 itself does not encode a protein and thus does not play a direct physiological, pharmacological, or disease-associated role. Pseudogenes are typically classified as "other" in molecular classification schemes, distinguishing them from protein-coding genes such as enzymes, receptors, or transporters.
None; pseudogene does not encode a functional product.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L34 pseudogene 6 (RPL34P6).